Current Studies

Last updated June 12, 2018

vials

Studies currently being conducted by the SIVS Clinical Trials Program (click on the ClinicalTrials.gov Identifier (NCT number) for more information
Recruiting

Current Studies - Recruiting

NCT03537508: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Sponsor: Sanofi Pasteur Principal Investigator: Richard Rupp, MD

NCT03486834: Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age

Sponsor: Merck Sharp & Dohme Corp Principal Investigator: Richard Rupp, MD
NCT03480763: A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)

Sponsor: Merck Sharp & Dohme Corp Principal Investigator: Richard Rupp, MD
Active, Not Recruiting

Current Studies - Active, Not Recruiting

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)    Principal Investigator: Richard Rupp, MD

NCT03207750: A phase IIIA, randomized, single-blind, multi-centric study to evaluate the immunogenicity, reactogenicity and safety of three doses of Pediarix®, Hiberix®and Prevenar 13®when co-administered with two doses of the PCV-free liquid formulation of GSK Biologicals' oral live attenuated HRV vaccine as compared to the currently licensed lyophilized formulation of the HRV vaccine in healthy infants 6-12 weeks of age

 Sponsor: GlaxoSmithKline      Principal Investigator: Richard Rupp, MD
NCT02987972: A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants

Sponsor: Merck Sharp & Dohme Corp    

Principal Investigator: Richard Rupp, MD, Pediatric Clinic, Galveston Island East
Principal Investigator: Mark Wolffarth, MD, Pediatric Clinic, League City (Bay Colony)

NCT02624947: A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants 

Sponsor: Novavax     Principal Investigator: George Saade, D

NCT00000000: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live-Attenuated Tetravalent Dengue Vaccine (V181) in Flavivirus-Naïve and Flavivirus-Experienced Healthy Adults

Sponsor: Merck Sharp & Dohme Corp  Principal Investigator: Richard Rupp, MD
NCT03512288: A Phase 2, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Infants

Sponsor: Pfizer Inc.       Principal Investigator: Richard Rupp, MD
NCT03090191: A phase III, placebo-controlled, randomized, observer-blinded, study to evaluate efficacy, and tolerability of a Clostridium difficile vaccine in adults 50 years of age and older

Sponsor: Pfizer Inc.    Principal Investigator: Richard Rupp, MD

SIVS Globe logo 021618